Cargando…

Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes

The present study sought to evaluate the cost-effectiveness of first-line (immediate) versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes, from the perspective of the Australian healthcare system. We developed a Markov model to simulate the progress of subj...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chin, Ken Lee, Ofori-Asenso, Richard, Si, Si, Hird, Thomas R., Magliano, Dianna J., Zoungas, Sophia, Liew, Danny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397228/ https://www.ncbi.nlm.nih.gov/pubmed/30824788 http://dx.doi.org/10.1038/s41598-019-40191-8

Ejemplares similares

Effect of Comorbidity Assessed by the Charlson Comorbidity Index on the Length of Stay, Costs and Mortality among Older Adults Hospitalised for Acute Stroke
por: Ofori-Asenso, Richard, et al.
Publicado: (2018)

Patterns of Medication Dispensation for Multiple Comorbidities among Older Adults in Australia
por: Ofori-Asenso, Richard, et al.
Publicado: (2018)

Patterns and Predictors of Adherence to Statin Therapy Among Older Patients: Protocol for a Systematic Review
por: Ofori-Asenso, Richard, et al.
Publicado: (2017)

Rethinking pandemic preparation: Global Health Security Index (GHSI) is predictive of COVID-19 burden, but in the opposite direction
por: Aitken, Tess, et al.
Publicado: (2020)

Early signs that COVID-19 is being contained in Australia
por: Chin, Ken Lee, et al.
Publicado: (2020)

Cost-Effectiveness of Canagliflozin Versus Dapagliflozin Added to Metformin in Patients With Type 2 Diabetes in China
por: Hou, Xingyun, et al.
Publicado: (2019)

Smell and Taste Dysfunction in Patients With COVID-19: A Systematic Review and Meta-analysis
por: Agyeman, Akosua Adom, et al.
Publicado: (2020)

The Cost-Effectiveness of Supplemental Carnosine in Type 2 Diabetes
por: Menon, Kirthi, et al.
Publicado: (2022)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Skipping Breakfast and the Risk of Cardiovascular Disease and Death: A Systematic Review of Prospective Cohort Studies in Primary Prevention Settings
por: Ofori-Asenso, Richard, et al.
Publicado: (2019)

Frailty Confers High Mortality Risk across Different Populations: Evidence from an Overview of Systematic Reviews and Meta-Analyses
por: Ofori-Asenso, Richard, et al.
Publicado: (2020)

The effectiveness and cost effectiveness of dark chocolate consumption as prevention therapy in people at high risk of cardiovascular disease: best case scenario analysis using a Markov model
por: Zomer, Ella, et al.
Publicado: (2012)

The Frequency of, and Factors Associated with Prolonged Hospitalization: A Multicentre Study in Victoria, Australia
por: Ofori-Asenso, Richard, et al.
Publicado: (2020)

Cost-effectiveness of health technologies in adults with type 1 diabetes: a systematic review and narrative synthesis
por: Pease, Anthony, et al.
Publicado: (2020)

The impact of diabetes on the productivity and economy of Bangladesh
por: Afroz, Afsana, et al.
Publicado: (2020)

Angiotensin converting enzyme genotypes and mortality from COVID-19: An ecological study
por: Aung, Ar K, et al.
Publicado: (2020)

Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post‐hoc analysis of concomitant add‐on versus sequential add‐on to metformin and of triple versus dual therapy with metformin
por: Del Prato, Stefano, et al.
Publicado: (2018)

Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis
por: Morton, Jedidiah I., et al.
Publicado: (2022)

Dapagliflozin, metformin, monotherapy or both in patients with metabolic syndrome
por: Cheng, Lan, et al.
Publicado: (2021)

Dapagliflozin versus saxagliptin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin
por: Rosenstock, Julio, et al.
Publicado: (2018)

Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis
por: Ofori-Asenso, Richard, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States
por: Neslusan, Cheryl, et al.
Publicado: (2018)

Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise
por: Nian, Hua, et al.
Publicado: (2020)

Evaluating optimal utilisation of technology in type 1 diabetes mellitus from a clinical and health economic perspective: protocol for a systematic review
por: Pease, Anthony, et al.
Publicado: (2018)

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System Perspective
por: Charokopou, M., et al.
Publicado: (2015)

Dapagliflozin Versus Vildagliptin as an Adjuvant to Metformin in Patients With Type 2 Diabetes Mellitus: A Randomized, Open-label Study
por: Gautam, Kumar, et al.
Publicado: (2023)

Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China
por: Gu, Shuyan, et al.
Publicado: (2016)

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR
por: Kuecker, Catherine M, et al.
Publicado: (2016)

Life-Threatening Acidosis With Metformin and Dapagliflozin Combination Therapy: A Case Report
por: Gupta, Sushan, et al.
Publicado: (2023)

Health and productivity burden of coronary heart disease in the working Indonesian population using life-table modelling
por: Uli, Regina E, et al.
Publicado: (2020)

Assessing the impact of smoking on the health and productivity of the working-age Indonesian population using modelling
por: Satyana, Regina P U, et al.
Publicado: (2020)

Association between Dietary Intake and Lipid-Lowering Therapy: Prospective Analysis of Data from Australian Diabetes, Obesity, and Lifestyle Study (AusDiab) Using a Quantile Regression Approach
por: Gadowski, Adelle M., et al.
Publicado: (2019)

Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
por: Vega-Hernandez, Gabriela, et al.
Publicado: (2017)

Treatment Dynamics in People Who Initiate Metformin or Sulfonylureas for Type 2 Diabetes: A National Cohort Study
por: Wood, Stephen, et al.
Publicado: (2021)

Diabetes Prevention and Treatment Strategies: Are we doing enough?
por: Backholer, Kathryn, et al.
Publicado: (2013)

Efficacy of the treatment with dapagliflozin and metformin compared to metformin monotherapy for weight loss in patients with class III obesity: a randomized controlled trial
por: Ferreira-Hermosillo, Aldo, et al.
Publicado: (2020)

Integrating the Biology of Cardiovascular Disease into the Epidemiology of Economic Decision Modelling via Mendelian Randomisation
por: Ademi, Zanfina, et al.
Publicado: (2022)

Global Incidence of Frailty and Prefrailty Among Community-Dwelling Older Adults: A Systematic Review and Meta-analysis
por: Ofori-Asenso, Richard, et al.
Publicado: (2019)

Dapagliflozin versus empagliflozin in patients with chronic kidney disease
por: Alnsasra, Hilmi, et al.
Publicado: (2023)

A closer look at the World Health Organization's prescribing indicators
por: Ofori-Asenso, Richard
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5753d44p4buotd9n0rlqckbejf